The A14 position of insulin tolerates considerable structural alterations with modest effects on the biological behavior of the hormone.
As part of our aim to investigate the contribution of the tyrosine residue found in the 14 position of the A-chain to the biological activity of insulin, we have synthesized six insulin analogues in which the A14 Tyr has been substituted by a variety of amino acid residues. We have selected three hydrophilic and charged residues--glutamic acid, histidine, and lysine--as well as three hydrophobic residues--cycloleucine, cyclohexylalanine, and naphthyl-(1)-alanine--to replace the A14 Tyr. All six analogues exhibit full agonist activity, reaching the same maximum stimulation of lipogenesis as is achieved with porcine insulin. The potency for five of the six analogues, [A14 Glu]-, [A14 His]-, [A14 Lys]-, [A14 cycloleucine]-, and [A14 naphthyl-(1)-alanine]-insulins in receptor binding assays ranges from 40-71% and in stimulation of lipogenesis ranges from 35-120% relative to porcine insulin. In contrast, the potency of the sixth analogue, [A14 cyclohexylalanine]insulin, in both types of assays is less than 1% of the natural hormone. The retention time on reversed-phase high-performance liquid chromatography for the first five analogues is similar to that of bovine insulin, whereas for the sixth analogue, [A14 cyclohexylalanine]insulin, it is approximately 11 min longer than that of the natural hormone. This suggests a profound change in conformation of the latter analogue. Apparently, the A14 position of insulin can tolerate a wide latitude of structural alterations without substantial decrease in potency. This suggests that the A14 position does not participate directly in insulin receptor interaction. Only when a substitution which has the potential to disrupt the conformation of the molecule is made at this position, is the affinity for the receptor, and hence the biological potency, greatly reduced.
Chu
Y C
YC
Department of Biochemistry, Mount Sinai School of Medicine, City University of New York, New York 10029-6574.
Zong
L
L
Burke
G T
GT
Katsoyannis
P G
PG
D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D000409:Alanine / Q000031:analogs & derivatives / Q000737:chemistry; D000596:Amino Acids / Q000032:analysis; D000818:Animals; D002417:Cattle; D003515:Cycloleucine / Q000737:chemistry; D005947:Glucose / Q000378:metabolism; D005971:Glutamates / Q000737:chemistry; D018698:Glutamic Acid; D006639:Histidine / Q000737:chemistry; D007328:Insulin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism; D008055:Lipids / Q000096:biosynthesis; D008099:Liver / Q000378:metabolism; D008239:Lysine / Q000737:chemistry; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000737:chemistry; D051381:Rats; D011972:Receptor, Insulin / Q000378:metabolism; D012756:Sheep; D013329:Structure-Activity Relationship; D013552:Swine; D014443:Tyrosine / Q000737:chemistry
D000596:Amino Acids; D005971:Glutamates; D007328:Insulin; D008055:Lipids; D003515:Cycloleucine; D018698:Glutamic Acid; D014443:Tyrosine; C028544:cyclohexylalanine; D010649:Phenylalanine; D006639:Histidine; C059031:1-naphthylalanine; D011972:Receptor, Insulin; D005947:Glucose; D008239:Lysine; D000409:Alanine